Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SPN-820 is a novel small molecule activator of the mechanistic target of rapamycin complex 1 (mTORC1) currently under phase 2 development for use in major depressive disorder.
Lead Product(s): SPN-820
Therapeutic Area: Psychiatry/Psychology Product Name: SPN-820
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Supernus Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
Under the terms of the agreement, Supernus and Navitor will jointly conduct a Phase II clinical program for NV-5138 in treatment-resistant depression (TRD).
Lead Product(s): NV-5138
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Supernus Pharmaceuticals
Deal Size: $475.0 million Upfront Cash: $25.0 million
Deal Type: Collaboration April 21, 2020